Check out the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (September 2nd-8th, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

Atypical ductal or lobular hyperplasia, LCIS, flat epithelial atypia, and future risk of developing breast cancer: meta-analysis 5- and 10-Year Risk Estimates👇 LCIS➡️9.3% - 11.8% ADH➡️6.6% - 13.9% ALH➡️9.7% - 15.4% LN➡️8.6% - 17.0% FEA➡️3.8% - 7.2% thebreastonline.com/article/S0960-…

Patients with residual disease (RD) after NACT are at high risk of recurrence. But are all RD equal? In this JAMA Oncology piece we dissect the anatomical, biological & immunological heterogeneity of RD, suggesting a framework to improve treatment tailoring. jamanetwork.com/journals/jamao…

Remarkable results of #Tdxd in HER2+ Brain mets in DB-012. Officially a solid option in these patients (even those with active mets). #bcsm #ESMO2024

Remarkable that RR in CNS will be the same as outside the CNS. The historical problem of treating CNS disease is not the 'blood brain barrier' so much as resistant disease and / or drugs that were not sufficiently active.

Some HER2+ tumors melt upon dual anti-HER2 Rx; others require chemo, or don’t respond to anything. Dissecting them, a key challenge with huge clinical impact. Find the latest understanding on anti-HER2 Rx tailoring in our latest article, led by Ada Waks. nature.com/articles/s4157…

Very true. A lot of companies are in a race to get their drugs approved for, nonetheless needed indications.

#esmo2024 Meghna Trivedi presents results from I-SPY2.2 Dato-DXd plus Durva. This personalized approach to therapy allows optimal efficacy with reduced toxicity in 50% with most achieving pCR without anthracyclines. Imp model for trials ⁦OncoAlert⁩

Couldn't agree more, my takeaways were: 🔑 aggressive disease (younger women and G3) not surprisingly had higher pCR to chemo 🔭 pCR leads to improved OS (5%) 🔮 ADCs for RD will hopefully significantly improve upon capecitabine #ESMO24 #ESMOAmbassadors Manon de Graaf

All good points by Vinay Prasad MD MPH breaking down the LEAP-012. There has been a trend of getting "too excited, too early" in the recent years. We all want to improve our patients' outcomes, but we want to wait for the right endpoints. #ESMO2024

Nice to see this analysis which provides insight into the role of OFS in ER+/HER2+ early BC. #bcsm #ESMO2024

A gift that is going to keep on giving. The POSITIVE trial is going to go down as one of the most important and influential breast cancer trials of all time. #bcsm #ESMO2024

It is time to design prospective de-escalation trials based on TILs in both HER2+ and TNBC. #bcsm #ESMO2024

Remarkable results. More fine tuning in the, hopefully, near future to figure out who does not need to be rolled into the operating room. #immunotherapy #ESMO2024 #coloncancer

#ESMO24 beautiful discussion by MarleenKokLab on KN522 OS presentation highlighting impact on young women, importance of QOL and urgent need for Biomarker research. OncoAlert

Day 3 #ESMO24 highlights: 1. #KN522: Update TNBC 2. #NIAGARA: resectable MIBC Tom Powles Petros Grivas 3. #CONTACT02: Update mCRPC Neeraj Agarwal, MD, FASCO 4. #NICHE2: dMMR Colon Ca Myriam Chalabi 1/5 #OncTwitter ESMO - Eur. Oncology OncoAlert #bcsm #gism #MedTwitter

3 year IDFS update from #NATALEE shows widening of the curve and benefit for addition of ribo across subgroups with anticipated safety results. #ESMO24 OncoAlert ESMO - Eur. Oncology

Here's the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (September 9th-15th, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

Updated (non-exhaustive) breast cancer treatment algorithms, now including adjuvant ribociclib and other recent updates. I am happy to be running out of space as treatment options continue to expand! OncoAlert #bcsm

Check out the newest #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (September 16th-22nd, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch